BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics has announced impressive results from its Phase 2 study on metastatic breast cancer, with a 55% one-year survival rate that surpasses the current standard of care. The study highlights the potential of BriaCell’s Bria-IMT™ therapy to improve survival even in patients who have not responded to other treatments. These promising findings set the stage for the company’s ongoing pivotal Phase 3 study.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
